PROPHYLACTIC INTRAVESICAL INSTILLATION THERAPY WITH ADRIAMYCIN (ADM) AND MITOMYCIN C (MMC) IN PATIENTS WITH SUPERFICIAL BLADDER CANCER

DOI Web Site
  • Ozaki Yujiro
    Department of Urology, Okayama University Medical School, Okayama Urological Cancer Collaborating Group
  • Tsushima Tomoyasu
    Department of Urology, Okayama University Medical School, Okayama Urological Cancer Collaborating Group
  • Nasu Yasutomo
    Department of Urology, Okayama University Medical School, Okayama Urological Cancer Collaborating Group
  • Akagi Takafumi
    Department of Urology, Okayama University Medical School, Okayama Urological Cancer Collaborating Group
  • Obama Tsuneaki
    Department of Urology, Okayama University Medical School, Okayama Urological Cancer Collaborating Group
  • Matsumura Yosuke
    Department of Urology, Okayama University Medical School, Okayama Urological Cancer Collaborating Group
  • Ohmori Hiroyuki
    Department of Urology, Okayama University Medical School, Okayama Urological Cancer Collaborating Group

Bibliographic Information

Other Title
  • 表在性膀胱腫瘍に対する制癌剤再発予防注入療法

Search this article

Abstract

Intravesical instillation of Adriamycin (ADM) and Mitomycin C (MMC) was carried out for the purpose of prophylaxis of the recurrence of superficial bladder cancers after TUR or TUC.<br>The eligible patients were allocated at random into the following 3 groups (ADM, MMC and control), for solitary or multiple tumors of bladder.<br>1) No treatment.<br>2) Intravesical instillation with ADM: 50mg of ADM in 100ml saline solution.<br>3) Intravesical instillation with MMC: 30mg of MMC in 100ml saline solution.<br>The drugs were given 6 times by instillations in 2 weeks after TUR or TUC, and there after for 2 days continuously every 4 weeks for 2 years.<br>In total 134 patients were investigated. Of them 103 patients were evaluable and 31 were eliminated as non-evaluable patients.<br>The cumulative non-recurrence rate was 73.6% in the ADM group, 63.4% in the MMC group and 22.5% in the control group after following up for 24 months. The cumulative non-recurrence rates of the 2 instilled groups (ADM, MMC) are significantly higher than that of the control group.<br>The side effects were relatively mild.<br>We consider that this instillation therapy with Adriamycin and Mitomycin C is useful for preventing the recurrence of bladder cancers.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top